

NCT02609048 comparison:

Summary:
CHIA has 24 criteria while your personal folder has 24 criteria
Total found criteria: 24/24
Total not Found: 0/24
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Must have given written informed consent (signed   │ Must have given written informed consent (signed   │
│ and dated) and any authorizations required by      │ and dated) and any authorizations required by      │
│ local law                                          │ local law                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ 18 to 75 years old (inclusive)                     │ 18 to 75 years old (inclusive)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male or female with a diagnosis of PBC, by at      │ Male or female with a diagnosis of PBC, by at      │
│ least two of the following criteria                │ least two of the following criteria                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of AP above ULN for at least six months    │ History of AP above ULN for at least six months    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive Anti-Mitochondrial Antibodies (AMA)       │ Positive Anti-Mitochondrial Antibodies (AMA)       │
│ titers (>1/40 on immunofluorescence or M2 positive │ titers (\>1/40 on immunofluorescence or M2         │
│ by enzyme linked immunosorbent assay (ELISA) or    │ positive by enzyme linked immunosorbent assay      │
│ positive PBC-specific antinuclear antibodies       │ (ELISA) or positive PBC-specific antinuclear       │
│                                                    │ antibodies                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented liver biopsy result consistent with PBC │ Documented liver biopsy result consistent with PBC │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ On a stable and recommended dose of UDCA for the   │ On a stable and recommended dose of UDCA for the   │
│ past twelve months                                 │ past twelve months                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AP ≥ 1.67 × ULN                                    │ AP ≥ 1.67 × ULN                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For females of reproductive potential, use of at   │ For females of reproductive potential, use of at   │
│ least one barrier contraceptive and a second       │ least one barrier contraceptive and a second       │
│ effective birth control method during the study    │ effective birth control method during the study    │
│ and for at least two weeks after the last dose.    │ and for at least two weeks after the last dose.    │
│ For male subjects, use of appropriate              │ For male subjects, use of appropriate              │
│ contraception (e.g., condoms), so their female     │ contraception (e.g., condoms), so their female     │
│ partners of reproductive potential do not become   │ partners of reproductive potential do not become   │
│ pregnant during the study and for at least two     │ pregnant during the study and for at least two     │
│ weeks after the last dose                          │ weeks after the last dose                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A medical condition, other than PBC, that in the   │ A medical condition, other than PBC, that in the   │
│ investigator's opinion would preclude full         │ investigator's opinion would preclude full         │
│ participation in the study or confound its results │ participation in the study or confound its results │
│ (e.g., cancer on active treatment)                 │ (e.g., cancer on active treatment)                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AST or ALT > 3 × ULN                               │ AST or ALT \> 3 × ULN                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total bilirubin > 2 × ULN                          │ Total bilirubin \> 2 × ULN                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Auto-immune hepatitis                              │ Auto-immune hepatitis                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Primary sclerosing cholangitis                     │ Primary sclerosing cholangitis                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known history of alpha-1-Antitrypsin deficiency    │ Known history of alpha-1-Antitrypsin deficiency    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known history of chronic viral hepatitis           │ Known history of chronic viral hepatitis           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Creatine kinase above ULN                          │ Creatine kinase above ULN                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum creatinine above ULN                         │ Serum creatinine above ULN                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For females, pregnancy or breast-feeding           │ For females, pregnancy or breast-feeding           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of colchicine, methotrexate, azathioprine, or  │ Use of colchicine, methotrexate, azathioprine, or  │
│ systemic steroids in the two months preceding      │ systemic steroids in the two months preceding      │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current use of fibrates, including fenofibrates,   │ Current use of fibrates, including fenofibrates,   │
│ or simvastatin                                     │ or simvastatin                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of an experimental treatment for PBC           │ Use of an experimental treatment for PBC           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of experimental or unapproved                  │ Use of experimental or unapproved                  │
│ immunosuppressant                                  │ immunosuppressant                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any other condition(s) that would compromise the   │ Any other condition(s) that would compromise the   │
│ safety of the subject or compromise the quality of │ safety of the subject or compromise the quality of │
│ the clinical study, as judged by the Investigator  │ the clinical study, as judged by the Investigator  │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
├───────────────────────────────────┤
│ Must have maximum age of 75 Years │
╘═══════════════════════════════════╛